{
  "ticker": "ANR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967687",
  "id": "02967687",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250709",
  "time": "0919",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmn7kbmr6flj.pdf",
  "summary": "- **Japanese Patent Grant**: Patent granted for \"Gastrointestinal Health Composition\" (GaRP) in Japan, valid until 9 October 2040. Follows similar grants in Hong Kong, Australia, and EU.  \n- **Anti-Obesity Project Progress**: Pre-clinical studies in diet-induced obese mice commenced; initial phase ~6 months, potential extension. Targeting GLP-1 stimulation for weight loss maintenance. Budget: >$350k allocated.  \n- **GaRP-IBS Trial Results**: Primary safety endpoint met; secondary endpoints showed statistically significant improvements in pain severity, frequency, and abdominal distension. Commercialisation discussions ongoing.  \n- **R&D Tax Incentive**: Application registered for 2024-2025 income period (confirmed 8 July 2025).  \n\n*No material trading or capital markets actions announced.*",
  "usage": {
    "prompt_tokens": 2372,
    "completion_tokens": 172,
    "total_tokens": 2544,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:42:22.575294"
}